TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06519929
Drug: Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A bolus of 1 mg/kg based on ideal body weight will be given over 10 minutes with a physician present and infusions will be started at 1 mg/kg/h based on IBW. Infusions will run continuously for the first 72 h and can be continued beyond that at the discretion of the treating team if pain persists. Patients will be assessed for LAST twice daily. Any patient with suspected LAST will have lidocaine infusion stopped and a lidocaine plasma level will be sent. If symptoms resolve, the lidocaine infusion can be restarted at a rate 25% lower. If pain is refractory to the lidocaine infusion and multimodal adjuncts, the infusion may be increased to a maximum of 1.5 mg/kg/h (during first 24 h only). The actual duration of the infusion as well as total lidocaine dose given in mg will be recorded. Stopping criteria for lidocaine will include the occurrence of new EKG changes for which an alternative explanation is not more likely as well as LAST symptoms.
Study: NCT06503679
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT06503679
Drug: Repaglinide
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06503679
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05398445
Drug: Rocatinlimab
Normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Rocatinlimab subcutaneously.
Study: NCT06212830
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 200 mg twice a day, starting from the night prior to the procedure and continue 48 hours after
Study: NCT06212830
Drug: Targin
Normalized name: Targiniq
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Targin 5 mg twice a day after the procedure for 48 hours
Study: NCT06212830
Drug: NSAID
Normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
Study: NCT06212830
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
Study: NCT05508152
Drug: Wound irrigation with amoxicillin-clavulanate in saline solution
Normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio.~For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~In the experimental arm of the study, the circulating nurse will prepare a solution of amoxicillin-clavulanate acid (1000 mg of antibiotic in 500 mL of saline) outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with the antibiotic solution, and the soaked gauze placed on the wound for 3 minutes.
Study: NCT05508152
Drug: Wound irrigation with a saline solution
Normalized name: Simply Saline Wound Wash
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio. For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~If the case belongs to the sham group, at the end of the intervention, the circulating nurse will prepare a sham solution contaning only normal saline outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with saline, and the soaked gauze placed on the wound for 3 minutes.
Study: NCT06411821
Drug: Ulixertinib
Normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg twice daily, for every 28-day cycle.
Study: NCT05498272
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg orally twice a day (D1-D30) for 6 Cycles (30 day Cycles)
Study: NCT05430867
Drug: Memantine Oral Tablet
Normalized name: memantine Oral Tablet
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memantine 20mg once-daily
Study: NCT05350189
Drug: Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At discretion of attending physician
Study: NCT06308653
Drug: Psilocybin 25 mg
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Psilocybin.
Study: NCT06308653
Drug: Psilocybin 5 mg
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active comparator is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 5 mg of Psilocybin.
Study: NCT05331742
Drug: Vaccine
Normalized name: VACCINES
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients who have received vaccine against coronavirus disease infection
Study: NCT04928352
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
Study: NCT04928352
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
Study: NCT00497120
Drug: acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06532331
Drug: ONO-7475
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06532331
Drug: ONO-4538
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06532331
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06532331
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06584435
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab is administered intravenously at a fixed dose of 240 mg every 3 weeks for 1 treatment cycle until tumor recurrence or intolerable toxic effects.
Study: NCT04785924
Drug: Imipenem+Relebactam
Normalized name: cilastatin / imipenem / relebactam
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antibiotic treatment for KPC producing CRE-containing gram-negative infections
Study: NCT04790045
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Core-needle biopsy to be performed before starting treatment in patients candidates to venetoclax-based regimens
Study: NCT04817540
Drug: Herzuma
Normalized name: Herzuma
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg IVF loading dose at first cycle -\> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle
Study: NCT06657066
Drug: Beclomethasone 200mcg, salbutamol 100mcg , Beclomethasone 200 mcg/Formoterol 6 mcg, 250 mg of lyophilized saccharomyces boulardii
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram plus Saccharomyces boulardii, available in sachet from employed in this research containing 250 mg of lyophilized saccharomyces boulardii. It was given daily for three months
Study: NCT06657066
Drug: Control (Standard treatment)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control arm will receive only standard treatment for asthma i.e Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram.
Study: NCT06604325
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All women recruited to Group A will receive tranexamic acid 1 gram in 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
Study: NCT05294900
Drug: paclitaxel/carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction chemotherapy : total 2 cycle every 3weeks as below:~* Paclitaxel 175mg/m2~* Carboplatin AUC5
Study: NCT04721015
Drug: ABBV-637
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT04721015
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT04721015
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Tablets
Study: NCT06672666
Drug: Hemp Derived Cannabidiol Extract
Normalized name: hemp
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be given the study drug in a titrated method of 50-150mgs per day for 4 weeks
Study: NCT04886700
Drug: SG001
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
Study: NCT05192213
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be allocated in a 1: 1 ratio to the treatment group, receiving intravenous Vitamin C (1.5 g every 6 hours), Thiamine (200 mg every 12 hours) and Hydrocortisone (50 mg every 6 hours) for 7 days
Study: NCT04831450
Drug: Cemiplimab-Rwlc
Normalized name: cemiplimab-rwlc
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 350 mg Cemiplimab administered via intravenous infusion over 30 minutes on Day 1 of a 21-day cycle.
Study: NCT06672549
Drug: Orforglipron
Normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally. ISA specific interventions will be listed in the ISA.
Study: NCT06602258
Drug: Lecanemab
Normalized name: Lecanemab
DrugBank: Lecanemab (DB14580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecanemab SC injection.
Study: NCT05588128
Drug: 18F-DCFpyL
Normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered to Cohort.
Study: NCT06387056
Drug: Rezvilutamide
Normalized name: Rezvilutamide
DrugBank: Rezvilutamide (DB19133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg by mouth once a day for 24 weeks.
Study: NCT06387056
Drug: Goserelin Microspheres for Injection
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.6mg by intramuscular injection once 4 weeks for 24 weeks.
Study: NCT06387056
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
Study: NCT06387056
Drug: Pamiparib
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg by mouth twice a day for 20 weeks.
Study: NCT06387056
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
Study: NCT06387056
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
Study: NCT06453694
Drug: Efgartigimod Alfa
Normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2,016 mg will be administered subcutaneously by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation.
Study: NCT06187506
Drug: Disitamab vedotin
Normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg, administered intravenously every three weeks
Study: NCT00189358
Drug: tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04349930
Drug: Cannabidiol vaginal suppository
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol vaginal suppository
Study: NCT05476796
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.
Study: NCT05476796
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
Study: NCT01218022
Drug: Losartan Potassium Tablets
Normalized name: Losartan Potassium Tablets
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06342362
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants would be randomly assigned to either the treatment group (receiving magnesium sulfate) or the control group (receiving a placebo or standard treatment).
Study: NCT05881993
Drug: CBP-4888
Normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: siRNA therapeutic
Study: NCT05564858
Drug: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia
Normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FDA022-BB05, intravenously infusion, q3w
Study: NCT04902885
Drug: Trilaciclib, carboplatin, etoposide，or Topotecan
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trilaciclib plus carboplatin, etoposide for first line patients ;Trilaciclib plus Topotecan for second or third line patients
Study: NCT04902885
Drug: placebo, carboplatin, etoposide，or Topotecan
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: placebo plus carboplatin, etoposide for first line patients ;placebo plus Topotecan for second or third line patients
Study: NCT05363007
Drug: nanoliposomal irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Upfront SI (Arm A): Upfront nanoliposomal irinotecan (80 mg/m2, day 1) + 5-FU/leucovorin (2400 mg/m2, 400 mg/m2) plus SI~Add-on SI (Arm B): Add-on SI following limited progression to prior nanoliposomal irinotecan (last dose used) + 5-FU/leucovorin (last dose used)
Study: NCT05213169
Drug: Apomorphine Hydrochloride 5mg/ml
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Product administered using an external continuous subcutaneous infusion pump.
Study: NCT05841849
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral aprepitant capsules 125mg for D1 before chemotherapy, 80mg for D2 and D3
Study: NCT05841849
Drug: Palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral palonosetron 0.5mg for D1 before chemotherapy; intravenous palonosetron 0.25mg for D1 before chemotherapy;
Study: NCT05841849
Drug: Fosaprepitant
Normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous fosaprepitant 150mg for D1 before chemotherapy
Study: NCT06407518
Drug: Midazolam oral solution
Normalized name: midazolam Oral Solution
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each individual administers the midazolam oral solution nightly from enrollment to the surgry.
Study: NCT02723435
Drug: Midostaurin
Normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05749588
Drug: A2: SHR-A1811 with Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~Camrelizumab: an anti-programmed death-1 (PD-1) antibody
Study: NCT06411184
Drug: Regulator T Cells
Normalized name: tisagenlecleucel
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Regulatory T-Lymphocytes 1\*10\^6/kg, 2\*10\^6/kg, 4\*10\^6/kg and 8\*10\^6/kg, respectively until restrictive toxic reaction occurs
Study: NCT04207710
Drug: Gebauer's Ethyl Chloride
Normalized name: Gebauer's Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical refrigerant spray
Study: NCT04718064
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days
Study: NCT05218629
Drug: Anlotinib, PD-1 inhibitor
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib, 8-12 mg/day, orally, day 1-14; PD-1 inhibitor 200 mg iv, every 21 days one cycle
Study: NCT06065722
Drug: Akynzeo
Normalized name: Akynzeo
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: OLANZAPINE
Study: NCT04670653
Drug: MOMETASONE FUROATE
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray
Study: NCT05008887
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fractional CO2 laser-assisted cutaneous delivery of 5-fluorouracil solution in stable, non-segmental vitiligo
Study: NCT05962307
Drug: Bulevirtide
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: dose of 2 mg/day subcutaneously
Study: NCT04788563
Drug: Original antihypertensive treatment (compulsively randomized arm)
Normalized name: jojoba oil, randomized
DrugBank: Jojoba oil (DB14252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, patients will maintain their original antihypertensive treatment.
Study: NCT04788563
Drug: Original antihypertensive treatment (voluntarily randomized arm)
Normalized name: jojoba oil, randomized
DrugBank: Jojoba oil (DB14252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, patients will maintain their original antihypertensive treatment.
Study: NCT04987203
Drug: Tivozanib
Normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tivozanib will be administered orally.
Study: NCT04987203
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered via intravenous infusion.
Study: NCT04926155
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
Study: NCT05796089
Drug: Etoposide with Carboplatin or Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The chemotherapy in this study is a standard treatment for extensive-stage small-cell lung cancer (EC-SCLC). The combination of chemotherapy (etoposide + carboplatin or etoposide + cisplatin) which the participant will receive is dependent on what is standard at the treatment centre.~Chemotherapy will be administered via an intravenous infusion every 3 weeks (21 days) for 4 cycles.
Study: NCT05796089
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The immunotherapy in this study is a standard treatment for ES-SCLC.~Participants will receive a dose of 1500 mg of Durvalumab via an intravenous infusion every 3 weeks (21 days) for 4 cycles, concurrently with chemotherapy.~A 1500 mg maintenance dose of Durvalumab will administered every 4 weeks after completion of chemotherapy (monotherapy).